Journal of Clinical Oncology
IF
32.96
Papers
117316
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Aleix PratH-Index: 53
#2Anwesha Chaudhury (Novartis)H-Index: 2
Last. Fei Su (Novartis)H-Index: 4
view all 12 authors...
PURPOSE The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials. METHODS A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trial...
1 CitationsSource
#1AnnaLynn M Williams (St. Jude Children's Research Hospital)
#2Qi Liu (U of A: University of Alberta)H-Index: 25
Last. Yutaka Yasui (St. Jude Children's Research Hospital)H-Index: 11
view all 7 authors...
Source
#1Ivonne Haffner (Leipzig University)H-Index: 2
#2Katrin Schierle (Leipzig University)H-Index: 9
Last. Florian Lordick (Leipzig University)H-Index: 57
view all 19 authors...
PURPOSE Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most eventually progress. The multicenter VARIANZ study aimed to investigate the background of response and resistance to trastuzumab in mGC. METHODS Patients receiving medical treatment for mGC were prospectively recruited in 35 German sites and followed for up to 48 months. HER2 status...
Source
#1Nirali N. ShahH-Index: 25
#1Nirali ShahH-Index: 1
Last. Crystal L. MackallH-Index: 74
view all 14 authors...
PURPOSECD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high...
Source
#1Guillermo Garcia-Manero (University of Texas MD Anderson Cancer Center)H-Index: 96
#2Valeria Santini (UniFI: University of Florence)H-Index: 39
Last. Aristoteles GiagounidisH-Index: 45
view all 28 authors...
PURPOSE Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia. METHODS Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI). RESULTS Two ...
Source
#1Nasheed Mohammad Hossain (LUC: Loyola University Chicago)H-Index: 7
#2Patrick J. Stiff (LUC: Loyola University Chicago)H-Index: 49
Source
#1Alan L. Ho (Cornell University)H-Index: 34
#2Irene BranaH-Index: 26
Last. Antonio GualbertoH-Index: 22
view all 25 authors...
PURPOSEMutations in the HRAS (mHRAS) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransfer...
Source
#1Leonard A. MattanoH-Index: 21
#2Meenakshi Devidas (St. Jude Children's Research Hospital)H-Index: 69
Last. Naomi J. Winick (UTSW: University of Texas Southwestern Medical Center)H-Index: 58
view all 20 authors...
PURPOSEChildren's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a ...
Source
#1Martin HutchingsH-Index: 31
#2Franck Morschhauser (Lille University of Science and Technology)H-Index: 52
Last. Michael Dickinson (Peter MacCallum Cancer Centre)H-Index: 19
view all 23 authors...
Purpose Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (Gpt) to reduce toxicity, are presented. Methods Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg Gpt. Dose-escalation...
1 CitationsSource
#1Melody A. Cobleigh (Rush University Medical Center)H-Index: 39
#2Stewart J. Anderson (University of Pittsburgh)H-Index: 55
Last. Norman Wolmark (University of Pittsburgh)H-Index: 23
view all 20 authors...
PURPOSEPreclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT alone vs concurrent RT plus T in...
Source
12345678910
Top fields of study
Cancer
Surgery
Pathology
Oncology
Physical therapy
Chemotherapy
Medicine